Novo Nordisk’s latest tie-up with OpenAI is being billed as a leap forward for medicine: a marriage of pharmaceutical heft and cutting-edge artificial intelligence that promises to deliver “new and better” treatments faster. But beneath the optimism lies a more complicated question: faster for what, and at what cost? The Danish drugmaker behind blockbuster weight-loss injections is the latest in a growing line of companies turning to AI to accelerate drug discovery. The techn

Allbirds, once held up as a poster child for low-impact fashion, is attempting a radical reinvention, but its new direction raises uncomfortable questions about the environmental cost of the tech that it hopes will save it. The San Francisco-founded company built its reputation on wool trainers that were marketed as a greener alternative to synthetic footwear, winning over environmentally conscious consumers and high-profile supporters alike. Now, however, it is seeking to re